Related Experiment Video

Updated: May 21, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

Fibroblast growth factor-23 and interleukin-6 are risk factors for left ventricular hypertrophy in peritoneal

Wei-hua Liu1, Qiao-ling Zhou, Xiang Ao

  • 1Department of Nephrology, Fujian Provincial Hospital, Fuzhou, China.

Journal of Cardiovascular Medicine (Hagerstown, Md.)
|June 26, 2012
PubMed

Insights

Fibroblast growth factor-23 (FGF-23) and interleukin-6 (IL-6) are linked to left ventricular hypertrophy (LVH) in continuous ambulatory peritoneal dialysis (CAPD) patients. These factors are independent risks and collaborate in causing LVH.

Area of Science:

  • Nephrology
  • Cardiology
  • Biochemistry

Background:

  • Left ventricular hypertrophy (LVH) is a significant predictor of cardiovascular mortality in dialysis patients.
  • Fibroblast growth factor-23 (FGF-23) and interleukin-6 (IL-6) are implicated in cardiovascular diseases (CVDs) among dialysis populations.

Purpose of the Study:

  • To investigate the association between FGF-23, IL-6, and LVH in continuous ambulatory peritoneal dialysis (CAPD) patients.
  • To determine if FGF-23 and IL-6 are independent risk factors for LVH in this cohort.

Main Methods:

  • Serum FGF-23 and IL-6 levels were measured in 62 CAPD patients and 30 healthy controls.
  • Standard laboratory parameters and LVH, assessed by echocardiography, were evaluated in CAPD patients.

Main Results:

  • CAPD patients exhibited higher serum FGF-23 and IL-6 levels compared to controls.
  • Elevated FGF-23 and IL-6 levels were observed in CAPD patients with LVH.
  • FGF-23 correlated positively with left ventricle mass index (LVMI) and phosphate; IL-6 correlated positively with LVMI and negatively with albumin and hemoglobin. FGF-23 and IL-6 levels were positively correlated.

Conclusions:

  • FGF-23 and IL-6 are independent risk factors contributing to LVH in CAPD patients.
  • Both FGF-23 and IL-6 play a collaborative role in the development of LVH in CAPD patients.
Abstract

More Related Videos

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Peritoneal Dialysis III: Nursing Management01:25

Peritoneal Dialysis III: Nursing Management

Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...